Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2870343 | 0.91 | BTK (0.43) | CSF1RPDGFRBFGFR1KDRMAOA | |
| SCHEMBL2857971 | 0.90 | FGFR1 (0.48) | CSF1RPDGFRBFGFR1KDRMAOA | |
| SCHEMBL2868581 | 0.85 | KDM4E (0.49) | PDGFRBFGFR1KDRMAOAKDM4E | |
| SCHEMBL2870232 | 0.84 | MAOA (0.43) | PDGFRBFGFR1KDRMAOAKDM4E | |
| SCHEMBL2870417 | 0.84 | PDGFRB (0.43) | CSF1RPDGFRBFGFR1KDRMAOA | |
| SCHEMBL2864303 | 0.83 | FGFR1 (0.48) | CSF1RPDGFRBFGFR1KDRBTK | |
| SCHEMBL2861085 | 0.83 | MAOA (0.42) | CSF1RPDGFRBFGFR1KDRMAOA | |
| SCHEMBL2865355 | 0.83 | FGFR1 (0.43) | CSF1RPDGFRBFGFR1KDRMAOA | |
| SCHEMBL2861337 | 0.82 | KDM4E (0.50) | PDGFRBFGFR1KDRMAOAKDM4E | |
| SCHEMBL2861165 | 0.81 | KDM4E (0.49) | PDGFRBFGFR1KDRMAOAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1719771-A1 | PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | MAP3K20, MAP4K5, MAP4K3 | CSF1R 2168/4885PDGFRB 375/4885FGFR1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.